Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases

NCT05414487 · clinicaltrials.gov ↗

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis
Neuromyelitis Optica Spectrum Disorder
Demyelinating Diseases of the Central Nervous System

Interventions

DRUG: Ofatumumab

Sponsor

Tianjin Medical University General Hospital